Investor Presentaiton
The Sales Growth of Marketed Biosimilars Accelerated; Multiple Pipeline
Products Planned for Global Presence
2023 sales revenue of biosimilars reached 3.43 billion RMB, 47% YoY growth
The biosimilar pipeline covered globally popular targets such as HER2, RANKL, CTLA-4, and conducted MRCT for global market
expansion
HANQUYOU BLA was under FDA review while working with business partners to expand global markets
Pre-
clinical
Clinical
Trial
3
HLX12-ramucirumab
HLX17-pembrolizumab
HLX1102-dupilumab
5
HLX05-cetuximab
HLX11-pertuzumab
HLX13-ipilimumab
HLX14-denosumab ①
HLX15-daratumumab
Marketed
Sales Revenue of Marketed Biosimilars (100 million RMB)
HANDAYUAN1
HANLIKANG1
HANBEITAI
HANQUYOU-overseas²
HANQUYOU-domestic
34.3
1.2
0.6
4
HANLIKANG--
rituximab
First biosimilar in China
HANQUYOU--
trastuzumab
+52%
5.2
0.9
23.4
0.5
5.5
15.0
0.4=
First Chinese trastuzumab
0.2
26.4
HANDAYUAN--
5.4
adalimumab
€0.6:
17.0
HANBEITAI--
bevacizumab
8.7
With international out-licensing
(ex China) and clinical trials
5
1. Revenue recognized by Henlius in 2023. Total revenue recognized by Fosun Pharma
2. Including Zercepac® and drug substance
2024 Henlius.
2021
2022
2023
2 HenliusView entire presentation